Curia Global Inc.
Albany, NY Doing business as Amri
- UEI
- ELCNZCS8GEA3
- CAGE
- 3D1R9
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- FY2025 rankings
-
Its parent company, UIC Parent Corporation, ranks:
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
-
- 325199 All Other Basic Organic Chemical Manufacturing
- 325411 Medicinal and Botanical Manufacturing
- 325412 Pharmaceutical Preparation Manufacturing
- 325413 In-Vitro Diagnostic Substance Manufacturing
- 325414 Biological Product (except Diagnostic) Manufacturing
- 325998 All Other Miscellaneous Chemical Product and Preparation Manufacturing
- 541380 Testing Laboratories and Services
- 541690 Other Scientific and Technical Consulting Services
- Corporate family
-
-
- Albany, NY XRAMJ5MJYK51
- Camarillo, CA T8FMANK6CPL1
- Albany, NY PW5LPREDN9N5
- Buffalo, NY PX3ZSADC4PN8
- Amri Ssci, LLC QFLDFFKYNJK2
- Y3KTFNZRLZB6
-
- SAM.gov registration date
- Physical address
- 21 Corporate Cir, Albany, NY 12203, USA
- Website
- curiaglobal.com
- Founded
- 1991
- Employees
- 1K-5K
- Estimated annual revenue
- $250M-$500M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | $4,651,551 |
| FY2025 | $2,485,395 |
| FY2024 | $7,457,406 |
| FY2023 | $10,237,721 |
Top agencies by obligations
| Rank | Agency | Obligated, FY2026–FY2027 | Share |
|---|---|---|---|
| 1 | Department of Health and Human Services | $4,586,551 | |
| 2 | Department of Veterans Affairs | $65,000 |
Contract vehicles
No active vehicles.
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| The Leland Stanford Junior University | 75N93020C00054 | $207,900 | |
| The Leland Stanford Junior University | 75N93020C00054 | $844,600 | |
| The Leland Stanford Junior University | 75N93020C00054 | $56,600 | |
| The Leland Stanford Junior University | 75N93020C00054 | $337,600 | |
| The Leland Stanford Junior University | 75N93020C00054 | $34,500 |
Latest 5 listed here. See the rest on GovTribe.
Grant awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Covid-19 action. Expand and accelerate domestic manufacturing related to medical, chemical and biological… | ACC Aberdeen Proving Ground | $13,214,795 |
Similar vendors
About the company
Curia Global Inc., doing business as Amri, is a for-profit contract development and manufacturing organization (CDMO) based in Albany, New York, that delivers exploratory chemistry, hit-to-lead chemistry, medicinal chemistry support, drug manufacturing and formulation, and cGMP manufacturing services to the National Institutes of Health as a prime contractor (91% of recent awards) and as a subcontractor on COVID-19 antiviral development work. The vendor competes on full-and-open contracts with no set-aside designations across its federal footprint.
Curia's customer concentration is extreme and singular: the National Institute of Neurological Disorders and Stroke (NINDS) accounts for 28 awards valued at $234.9 million combined potential value, the National Institute of Allergy and Infectious Diseases (NIAID) holds 24 awards at $127.4 million, and the National Institute on Drug Abuse (NIDA) carries 23 awards at $112.4 million. These three NIH institutes represent 75 of Curia's 101 awards and an estimated $474.7 million in combined potential value—approximately 94% of the vendor's federal footprint. The National Center for Advancing Translational Sciences (NCATS) and the National Institute on Aging round out the active set with secondary volume. Two Department of Veterans Affairs orders total $105 thousand. Representative prime work includes a $3.8 million delivery order from NINDS (September 2026) for exploratory and hit-to-lead medicinal chemistry under the Medicinal Chemistry Support Program for Therapeutic Development (MCSP), a $3.14 million delivery order from NINDS (September 2024) for drug manufacturing and formulation under the Drug Manufacturing and Formulation Program (DMFP), a $1.78 million purchase order from NIDA (September 2024) for non-GMP synthesis of compounds targeting KIAA0203 protein binding for Alzheimer's drug development, and a $1.9 million delivery order from NIAID (July 2024) for nonclinical services supporting interventional agents for infectious diseases.
Curia holds positions on four named NIH IDIQs. The Indefinite Delivery Contract HHSN271201800001I (Medicinal Chemistry Support Program for Therapeutic Development) carries 26 task orders valued at $62.1 million combined potential value. The Drug Manufacturing and Formulation Program (DMFP) supports 13 task orders at $16.3 million combined potential value. The Nonclinical Services for Development of Interventional Agents IDIQ carries 12 task orders at $7.4 million combined potential value. The CRO Support for NCATS Drug Substance Development and Manufacture IDIQ anchors 4 task orders at $7.3 million combined potential value. Additionally, Curia holds two multiple-award IDIQs awarded in 2026: a $49.7 million CMC services contract from NIDA (August 2026, completion May 2031) spanning small molecules, peptides, and biopharmaceuticals, and a $50 million DMFP contract from NINDS (May 2026, completion May 2036) for API scale-up, formulation, analytical methods development, and stability testing.
Award activity peaked in 2022 (14 awards) and 2024 (12 awards), with 2025 showing a marked drop to 3 awards and 2026 recovering to 8 awards as of September. Ten awards carrying combined potential value of $14.1 million reach ultimate completion inside the next twenty-four months and face recompete exposure. Curia's subcontractor role centers on COVID-19 antiviral development; the vendor performs non-GMP synthesis and manufacturing of small molecule candidates (STF-2586, STF-4326) under subagreements with The Leland Stanford Junior University, with sub work spanning May 2024 through June 2026.
SCI-reported invoiced revenue on federal service contracts shows $49.5 million across FY2022–FY2025, with significant scale-up in FY2024 ($32.3 million across 105 FTEs reported). The FY2024 spike reflects substantial delivery-order execution against the MCSP and DMFP vehicles; FY2025 SCI reporting stands at zero, likely reflecting reporting lags on newer awards. On federal services contracts captured in SCI, median government-paid rates run around $138/hr, with senior labor pricing through $218.50/hr and junior rates from $103.25/hr. Across SCI-reportable prime contracts, the vendor self-performed 100% of contractor hours with no subcontractor engagement. The corporate structure includes six named subsidiaries: Curia Albany R&D LLC, Curia Bio California Inc., Amri Ssci LLC, Curia Bio Inc., Curia Buffalo R&D LLC, and Whitehouse Analytical Laboratories LLC, with work performed across Albany, Buffalo, and Dockweiler, California, and international locations including Spain.
Quick answers
Is Curia Global Inc. registered in SAM.gov?
Yes. Curia Global Inc.'s SAM.gov registration is active through May 18, 2027.
Which contract vehicles does Curia Global Inc. hold?
Curia Global Inc. holds a place on 3 federal contract vehicles, including Nonclinical Services for Development of Interventional Agents, DMFP and CRO Support for NCATS Drug Substance Development and Manufacture.
How much has Curia Global Inc. received in federal contracts?
Federal contracts obligated $2,485,395 to Curia Global Inc. in fiscal year 2025 and $24,832,073 in fiscal years 2023 through 2027.
How does Curia Global Inc. rank among federal contractors?
Curia Global Inc.'s parent company, UIC Parent Corporation, ranked #32 in NAICS 325411, #53 in NAICS 325412 and #69 in PSC AN13 in FY2025.
What is Curia Global Inc.'s most recent federal award?
Curia Global Inc.'s most recent federal contract award is Exploratory chemistry and HIT-to-lead chemistry option. Medicinal chemistry support program for therapeutic development… (75N98026F00001), from Office of Logisitics and Acquisition Operations (NIH), on September 21, 2026.
On GovTribe
See Curia Global Inc.'s full federal record
- Federal contract awards
- IDV awards
- Contract vehicles
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors